Wednesday, 17 Oct 2018

You are here

The Diverse Fate of Seronegative Rheumatoid Arthritis

A Finnish Rheumatology Center followed 435 early, seronegative rheumatoid arthritis (RA) patients for 10-years and found that only 3% became erosive or seropositive RA. They also found that 32% could not be further reclassified, and that the remaining 65% evolve into another diagnosis, led by polymyalgia rheumatica (16%), psoriatic arthritis (11%), spondyloarthritis (9%), and osteoarthritis (10%).  

Between 1997-2005  they enrolled 1030 patients into the early RA clinic at the Jyväskylä Rheumatology Centre. They included 435 seronegative cases (42%), of whom 69% were women, and prospectively followed patients for a ten-year period.

Among the 435 seronegative cases, the 10-year outcomes revealed:

  • 13 (3%) could be reclassified as seropositive or erosive RA
  • 68 (16%) cases of polymyalgia rheumatica
  • 46 (11%) psoriatic arthritis
  • 47 (10.8%) seronegative spondyloarthritis 
  • 45 (10%) osteoarthritis
  • 38 (8.7%) spondyloarthritis
  • 15 (3.4%) plausible reactive arthritis
  • 10 (2.3%) gout
  • 17 (3.9%) pseudogout
  • 6 (1.4%) paraneoplastic arthritis
  • 6 (1.4%) juvenile arthritis
  • 2 (0.5%) haemochromatosis
  • 3 (0.7%) ankylosing spondylitis
  • 2 (0.5%) giant cell arteritis
  • 8 miscellaneous diagnoses.
  • 41 (9.4%) had transient arthritis
  • 49 (11.2%) remained were not reclassifed.

After an initial diagnosis of seronegativity, prolonged follow-up revealed significant heterogeneity and reclassification of the inital diagnosis. Therefore seronegative arthritis should not be considered as a homogenous entity.

(Editor's note: This is a very interesting study. I'm amazed that only 14% kept a diagnosis of RA, but this may be a regional issue. While many Scandinavian cohorts such as these may have more seronegative spondyloarthritis patients manifesting as polyarthritis, the diversity of other subsequent diagnoses is interesting, if not humbling. One thing said by Dr. Ronan Kavanaugh on RheumNow some time ago was that "In seronegative patients in remission for years always consider withdrawing DMARD". I would add to that by saying you should always consider alternative diagnoses the longer you call someone "seronegative" RA.)

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Predictive Risk Factors for Uveitis in JIA

Researchers from Germany have studied a large cohort of juvenile idiopathic arthritis (JIA) patients and shown that JIA disease activity scores and laboratory biomarkers could be used to better define the group of JIA patients at high risk of uveitis onset.

Elder Rheumatoids Less Likely to Receive Biologics

Multiple studies have shown that elderly rheumatoid arthritis (RA) patients tend to be under-treated and receive DMARD therapies less often than younger RA patients. Now a VAMC study shows that the elderly are less likely to receive biologic agents yet are as likely to be subjected to glucocorticoid use.

Long-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis

Only inhibitors of IL-1 (canakinumab) and IL-6 (tocilizumab) are FDA approved for use in children with systemic onset juvenile idiopathic arthritis (sJIA). Now, long-term data from the extension studies from two phase III studies shows that canakinumab yields long-term improvements with reduced glucocorticoid dosing with no new safety findings with long-term use.

Defining Refractory Rheumatoid Arthritis

Researchers from the British Society for Rheumatology Biologics (BSRBR) set out to define under what circumstances will rheumatoid arthritis (RA) patients manifest biologic disease-modifying antirheumatic drugs (bDMARDs) refractory disease.

Using the patients from the BSRBR Register (2001 to 2014) they defined patients as bDMARD refractory when they initiated their third class of bDMARD.

Venous Thromboembolism Increased with Rheumatoid Arthritis, Not with TNF Inhibition

Venous thromboembolism (VTE) is a common adverse event throughout medicine and includes both pulmonary embolism (PE) and deep vein thrombosis (DVT).   The cost of diagnosing a thromboembolic event is approximately $4000 - $5550, while the annual cost of treating one case of VTE is between $17,000 and $19,000. The impact of VTE is substantial.